BlueCrest Capital Management’s Integra LifeSciences IART Stock Holding History

BlueCrest Capital Management’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-28,999	Closed	-$1.91M	–	1121
2018 Q3	$1.91M	Sell	28,999 -150,671	-84%	-$9.36M	0.05%	271
2018 Q2	$11.6M	Buy	+179,670	New	+$11.1M	0.3%	57
2015 Q3	–	Sell	-73,394	Closed	-$1.83M	–	940
2015 Q2	$1.83M	Buy	+73,394	New	+$1.96M	0.05%	376

Other funds holding IART

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlueCrest Capital Management's IART Position: Q4 2018 in Review

BlueCrest Capital Management sold out of Integra LifeSciences (IART) in Q4 2018, closing a stake of 28,999 shares — an estimated $1.91M sold.

BlueCrest Capital Management first reported a position in IART in Q2 2015 and held it in 3 quarters. The position peaked at $11.6M in Q2 2018. 248 funds tracked by Wall St. Rank hold IART as of Q4 2018.

BlueCrest Capital Management reported no remaining Integra LifeSciences position as of Q4 2018 after selling out during the quarter.
BlueCrest Capital Management sold 28,999 Integra LifeSciences shares in Q4 2018, an estimated $1.91M.
BlueCrest Capital Management first reported a position in Integra LifeSciences in Q2 2015 and held it in 3 quarters.
BlueCrest Capital Management's Integra LifeSciences position peaked at $11.6M in Q2 2018.
248 funds tracked by Wall St. Rank held Integra LifeSciences as of Q4 2018.

Based on BlueCrest Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.